Routine Intracoronary Imaging-guided Left Main Coronary Intervention

Study population and design

The LM-JANHO is a multicenter, retrospective, observational registry study. In total, 806 consecutive patients who underwent LM-PCI with a drug-eluting stent (DES) between January 2016 and December 2020 were retrospectively enrolled from 19 institutes in the Japanese National Hospital Organization group.

The inclusion criteria were as follows: (1) de novo LM lesions including significant stenosis in the LM (≥50%) and/or daughter branches (≥75%) within a distance of 5 mm from the carina, which were treated with DES implantation in LM or crossover from LM to daughter branches; (2) suitable lesion for DES implantation in the LM; (3) patient age >20 years; and (4) tolerability of dual antiplatelet therapy for >6 months. The exclusion criteria were as follows: (1) in-stent restenosis lesions; (2) chronic total occlusion in the LM or adjusting branches; (3) the left anterior descending artery (LAD) and/or left circumflex artery (LCX) protected by prior CABG; (4) female with possible or definite pregnancy; (5) unsuitable candidate as judged by the responsible doctor, and (6) refusal to provide personal information for the study after receiving study information, in accordance with the opt-out system.

After the exclusion of 38 patients (inclusion criteria unmet in 26, lost to follow-up in 11, physician’s decision in one) and 25 patients with any deficit of 1-year follow-up data, the data of 743 patients were analyzed (Figure 1). The study protocol was approved by the Institutional Review Board of the Japanese National Hospital Organization and each attending hospital. This study was conducted using an opt-out system and was disclosed to the patients and requirement for informed consent was waived. The study protocol was developed in accordance with the Declaration of Helsinki and registered in the University Hospital Medical Information Network (ID: UMIN 000037332) prior to the initiation of enrollment.

• Download figure
• Open in new tab

Figure 1.

Study flow of the extraction of the analyzed patients.

Percutaneous coronary intervention protocol

All patients were treated with sufficient periprocedural heparin and dual antiplatelet therapy with aspirin (100 mg) and either clopidogrel (50–75 mg) or prasugrel (3.75 mg), which was continued for at least 6 months. In cases with deficits in PCI initiation, the procedure was performed after administering the loading dose (aspirin 200 mg, clopidogrel 300 mg, and prasugrel 20 mg). Imaging was strongly recommended before PCI to assess the lesion and select the optimal therapeutic device and after the PCI procedure for its optimization. The use of IVUS or OCT/OFDI was at the operator’s discretion. If any stent failure (stent malapposition >400 μm, insufficient stent expansion [<80%] compared with the mean value of proximal and distal references, and stent deformation) or serious dissection in the SB or stent proximal and/or distal edges was observed on imaging, prompt additional treatment was performed. The proximal optimal technique (POT), using a short balloon according to the LM vessel size, was recommended; however, its use relied on the operator’s discretion after the imaging assessment for LM stent expansion. After LM crossover stenting to the LAD or LCX, opposite branch ostial dilation and the choice of method (kissing balloon inflation [KBI] or opposite branch dilation alone) were also dependent on the operator’s discretion.

Data collection

Patient background, lesion characteristics, on-site visual assessment of coronary angiography, PCI procedure, medical treatment, and clinical outcome at 1-year follow-up were registered from each hospital to the REDCap system, a web-based application designed for streamlined data collection and management, in Osaka Metropolitan University Hospital center for clinical research and innovation.

In this study, acute coronary syndrome included acute myocardial infarction accompanied by elevated cardiac biomarker levels with or without ST elevation on electrocardiography and unstable angina, defined as new-onset or increased-severity angina within 1 month, resting angina, and postinfarction angina without elevated cardiac biomarker levels. Stable angina was defined as stable symptoms during high exertion, with no chest pain at rest in the past month. Silent myocardial ischemia was defined as the objective evidence of myocardial ischemia without evident chest symptoms. Cardiogenic shock was defined as a sustained episode of systolic blood pressure <80 mmHg and cardiac index <1.8 L/min⸱m², determined to be secondary to cardiac dysfunction, and/or the requirement of a parenteral inotropic or vasopressor agent or mechanical support to maintain blood pressure and cardiac index within 24 h before PCI. Pulmonary edema was defined as symptoms of heart failure within 24 h before PCI, including dyspnea on mild activity, orthopnea, body fluid retention, moist rales, and neck vein distention, which were equivalent to Congestive Heart Failure in the New York Heart Association functional classification class IV. Cardiac death was defined as death due to cardiac diseases, including heart failure, fatal arrhythmia, and sudden death. Vascular death was defined as death due to a vascular disease, except for coronary artery disease, such as diseases of the cerebrovascular artery, aorta, and peripheral and pulmonary arteries. Target lesion revascularization (TLR) was defined as any revascularization by PCI or CABG in the treated LM and adjusting proximal LAD and LCX within 5 mm from the branch ostium. Target vessel revascularization (TVR) was defined as revascularization of the LM, LAD, or LCX. Clinically driven revascularization included TVR and non-TVR. Stent thrombosis included definite and probable stent thrombosis as defined by the Academic Research Consortium. Cerebrovascular disorders included stroke with any new-onset neurological deficit due to the occlusion of the cerebrovascular artery and cerebrovascular hemorrhage, except for traumatic hemorrhage. Successful PCI was defined as the achievement of Thrombolysis in Myocardial Infarction flow grade III with residual stenosis of ≤25% in the target lesion¹⁶.

Endpoint

Major adverse cardiovascular and cerebrovascular events (MACCE) were defined as composite endpoints of the following at 1-year follow-up: all-cause death, cerebrovascular disorder, any clinically driven revascularization, and myocardial infarction.

Statistical analyses

Continuous variables are expressed as mean±standard deviation. Categorical variables are presented as percentages. Cox proportional hazard models were constructed to evaluate the association between each patient background, lesion characteristics, PCI procedures, and MACCE. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. The rates of MACCE incidence between patient background, legion characteristics, PCI procedures were compared by estimating cumulative incidence functions against the days from PCI. All reported p-values were determined by two-sided analysis, and p-values <0.05 were considered significant. Analyses were performed using the R software (version 4.2.2) (R Foundation for Statistical Computing, Vienna, Austria).

Baseline patient characteristics

Baseline patient characteristics are summarized in Table 1. Increased prevalence rates of male sex (78.7%), dyslipidemia (71.0%), diabetes mellitus (49.3%), prior myocardial infarction (25.2%), and prior PCI or CABG (43.6%) were observed. The mean left ventricular ejection fraction was 56±15%. Acute coronary syndrome was observed in 31.2% of the patients, and a severe hemodynamic collapse state (cardiogenic shock, cardiopulmonary arrest, and pulmonary edema) was observed in 2.4–6.1% of the patients. Canadian Cardiovascular Society (CCS) class ≥3 was observed in 39.3% of the patients.

Lesion background

The backgrounds of the lesions are shown in Table 1. LM bifurcation was observed in 78.0% of the patients, and the most prevalent Medina classification was 1-1-0 lesion (30.1%) and true bifurcation lesion, which included significant stenosis in both the main vessel (MV) and SB, accounted for 34.7%. Angiographically nonsignificant LM lesions (Medina 0-x-x) were included in 30.9% of the patients because of the identification of LM atherosclerotic plaques on intracoronary imaging.

PCI procedures

The PCI procedures are presented in Table 2. Radial access was frequently used in 70.1% of the patients, and most patients were treated with 6- and 7-Fr guiding systems (51.9% and 41.8%, respectively). Imaging guidance was routinely performed (97.7%), and IVUS and OCT/OFDI were performed in 86.5% and 12.2% of the patients, respectively. A current-generation DES was implanted in all patients, except for one in which a bare metal stent was used according to the physician’s discretion. Two-stent deployment in the LM bifurcation was performed in 8.8% of the patients, and elective procedure was performed in only 14 patients (1.9% of the entire cohort). The stenting technique was performed in the sequence of culottes, T-stenting, and crush stenting. The POT was performed in 53.1% of the patients treated with one-stent deployment. KBI or SB dilation alone was performed in 75.0% of the patients. A mechanical cardiac support device was used in 16.4% of the patients (intra-aortic balloon pumping, 15.8%; extracorporeal membrane oxygenation, 2.7%). Modification of calcified lesions was performed using rotational or orbital atherectomy (9.2%) and a scoring balloon (19.7%). MV stent size was 3.5–4.0 mm in 63.0% and 3.0–3.5 mm in 30.8% of the patients, and SB stent size was 3.0–3.5 mm in 41.0% and 2.5–3.0 mm in 34.9% of the patients. The PCI success rate was 98.6%.

Adverse events at 1-year follow-up

Adverse events at the 1-year follow-up are shown in Table 3. The rates of all-cause death, cerebrovascular disorders, clinically driven revascularization, and myocardial infarction were 8.9%, 1.2%, 8.2%, and 1.9%, respectively. MACCE, which were a composite of these events, were observed in 17.5% of the patients. TLR and cardiac death occurred in 2.0% and 3.4% of the patients, respectively. The cumulative curve of MACCE showed a gradual increase (Figure 2a), whereas that of all-cause death peaked within 30 days and plateaued at 1 year (Figure 3a).

• Download figure
• Open in new tab

Figure 2.

Cumulative curve of major adverse cardiovascular and cerebrovascular events. (a) Entire group. (b) The groups using or not using a mechanical cardiac support device (MCS). (c) Canadian Cardiovascular Society functional angina classification. (d) The groups treated with a single stent, two stents, and left main shaft stenting alone. (e) The groups of radial and nonradial access. (f) The groups of true bifurcation lesion, non-true bifurcation lesion, and non-bifurcation lesion.

• Download figure
• Open in new tab

Figure 3.

Cumulative curve of all-cause mortality. (a) Entire group. (b) The groups using or not using a mechanical cardiac support device (MCS). (c) Canadian Cardiovascular Society functional angina classification. (d) The groups treated with a single stent, two stents, and left main shaft stenting alone. (e) The groups of radial and nonradial access. (f) The groups of true bifurcation lesion, non-true bifurcation lesion, and non-bifurcation lesion.

Risk in major adverse cardiovascular and cerebrovascular events

Multivariate analysis of the risk of MACCE is shown in Table 4. Independent factors that elevated the risk included CCS ≥class III (HR, 2.07; 95% CI, 1.39–3.07; p<0.001), mechanical cardiac support device use (HR, 2.17; 95% CI, 1.43–3.30; p<0.001), and two-stent implantation (HR, 2.49; 95% CI, 1.48–4.18; p<0.001). Factors that reduced the risk were left ventricular ejection fraction −10% increase (HR, 0.72; 95% CI, 0.52–0.99; p=0.041) and radial access (HR, 0.62; 95% CI, 0.42–0.91; p=0.015). The cumulative curve of MACCE showed higher rates of mechanical cardiac support device use (Figure 2b), CCS classes III and IV (c), two-stent implantation (d), and nonradial access (e). The cumulative curve of all-cause death showed higher rates of mechanical cardiac support device use (Figure 3b), CCS class IV (c), and nonradial access (e), which peaked within 30 days.

Effect of routine imaging guidance in LM-PCI

Imaging guidance in LM-PCI demonstrated a lower incidence of composite endpoints of all-cause death, restenosis, or definite stent thrombosis (HR, 0.65; 95% CI, 0.50–0.84) and all-cause death alone (HR, 0.62; 95% CI, 0.47–0.82) in 2468 patients of the Swedish Coronary Angiography and Angioplasty Registry, in which IVUS guidance was used in 25.2% of the patients². In 11,264 unprotected LM-PCI procedures performed in England and Wales, analysis of 5056 pairs of imaging- and angio-guided PCIs after propensity matching showed that the imaging-guided PCI presented a lower incidence of 12-month mortality than the angio-guided PCI (odds ratio [OR], 0.660; 95% CI, 0.57–0.77)⁷. A meta-analysis of comparison between IVUS guidance (2096 patients) and angio-guidance (1984 patients) in LM-PCI also exhibited a lower incidence of all-cause death (OR, 0.46; 95% CI, 0.30–0.71), cardiac death (OR, 0.47; 95% CI, 0.29–0.77), and composite endpoints, including stent thrombosis, myocardial infarction, cardiac death, and all-cause death (OR, 0.42; 95% CI, 0.26–0.67)³. However, imaging guidance was employed for complex lesions in these studies, and the efficacy of routine imaging in every LM-PCI has not been elucidated.

The present study included cases with acute myocardial infarction and cardiogenic shock that were excluded in the other previous studies of the imaging-guided LM-PCI^{3, 5–7, 17}. Therefore, all-cause death (8.9% vs. 2.5–9.0%) and cardiac death at 1 year (3.4% vs. 0.8–2.4%) were observed more frequently in the present study than in previous studies. However, there was a similar incidence rate of TVR (4.6% vs. 4.2–6.7%) and lower incidence rates of TLR (2.0% vs. 2.7–7.7%), stent thrombosis (0.3% vs. 0.5–1.7%), and myocardial infarction (1.9% vs. 1.5–11.2%), indicating that optimal PCI was induced by imaging guidance in survivors after acute coronary events. The following factors contribute to the efficacy of routine imaging guidance in LM-PCI: first, the optimal device selection in terms of size and length was based on pre-PCI imaging, which decreased additional stenting due to overdilation or inappropriate positioning of the balloon or stent in the plaque-rich area. Information concerning plaque morphology, thrombus burden, and intracoronary calcification severity was also useful for appropriate preparation before stenting. Second, some atherosclerotic plaques were identified by intracoronary imaging in the angiographically insignificant LM lesions, which increased LM crossover stenting in the Medina (0-x-x) lesions. In this study, this type of lesion was observed in 30.9% of the patients, whereas in previous studies with limited use of imaging, it was observed in 0–21.5% of the patients^18–21. Third, more appropriate PCI optimization for sufficient stent expansion, less stent malapposition or deformation, and navigation of optimal SB guidewire crossings were promoted. Accurate assessment of SB dissection or stenosis after balloon dilation on intracoronary imaging resulted in a decrease in two-stent deployment in this study (8.8%). Elective two-stent deployment was performed in only 1.9% of the patients, and fewer escalations from provisional stenting (6.9%) were noted. Thus, local effectiveness of imaging-guided PCI on LM lesion was prominent in less TLR (2.0%) and cardiac death (3.4%) in this study compared with the prior Japanese registry study (AOI registry) (TLR: 9.1% [bifurcation]/11.0% [non-bifurcation], cardiac death: 6.6%/5.0%¹⁹) or randomized studies comparing provisional and elective two stenting with the limited use of imaging guidance and exclusion of acute myocardial infarction and cardiogenic shock (EBC MAIN, TLR: 6.1% [provisional stent]/9.3% [two stents]²¹; DK Crush V, TLR: 10.7%/5.0%, cardiac death: 1.3%/2.1%²⁰).

Risk of MACCE

CCS class ≥III and mechanical cardiac support device use were directly related to the severe hemodynamic collapse state, which might result in cardiac death in acute phase. As nonradial access was adopted more frequently in an unstable hemodynamic state with weak pulsation of the radial artery, it was also associated with the risk of cardiac death. In fact, the group with these factors had elevated mortality within 30 days and reached a plateau at 1 year (Figure 3). Even with technical improvements in LM-PCI under imaging guidance, the initial myocardial damage induced by LM ischemia cannot be effectively relieved.

Lower left ventricular ejection fraction was identified as an independent risk factor for MACCE. This was a result of LM ACS that led to severe left ventricular damage or ischemic cardiomyopathy that had already presented with multiple-vessel diseases, including LM lesions. A lower left ventricular ejection fraction was associated with heart failure recurrence, fatal arrhythmic events, and more frequent coronary revascularization.

Two-stent deployment was also an independent risk factor for MACCE. Higher risk^{18, 19, 22, 23} of two-stent deployment was demonstrated in previous studies in which first-generation DES were mainly used. However, similar^{21, 23} or superior clinical outcomes^{20, 24} compared with provisional stenting have been reported in recent studies that used current-generation DES. In the present study, two-stent deployment was used in a limited manner for more complex lesions (8.8%). More than 20% of the cases that would have been treated with elective two-stent deployment in other studies with limited use of intracoronary imaging were treated with provisional stenting in this study. However, true bifurcation lesions were not identified as risk factors for MACCE, and some SB lesions were left with dissection or incomplete full vessel dilation. Angiographically hazy images after pre-dilation in the SB were likely to promote more elective two-stent deployment or escalation to provisional two stenting in other studies. Escalation to provisional two stenting was observed in 22–47% of the patients owing to suboptimal findings in the SB, which were mainly assessed by angiographical diameter stenosis²⁵ and have been revealed to be overestimated with physiologically insignificant stenosis in 30% of the patients²⁶. Although definite imaging criteria were not established in this study, individual operators decided to perform additional SB stenting more strictly according to imaging findings, such as intimal flap, which threatens vessel occlusion, progression of hematoma, and insufficient lumen dilation with concrete plaque remaining. Although suboptimal angiographic findings remained in some true bifurcation lesions, they were not associated with worse clinical outcomes in imaging-guided LM-PCI. As most two-stent deployments were adopted in cases with suboptimal SB balloon dilation or multiple vessel involvement, diffuse lesions, hard calcification, rich plaque burden, and stent landing in the distal plaque were likely to be present, requiring more vessel revascularization. Therefore, comprehensive management strategies that consider plaque debulking, aggressive medical therapy, and switching to CABG after lesion assessment using intracoronary imaging are required.

Contemporary PCI techniques

Study limitations

The present study has the following limitations. 1) The study did not adopt a randomized trial design, with 97.7% of cases treated under imaging guidance. Consequently, the study design does not facilitate a direct assessment of the efficacy of imaging guidance in comparison with angio-guidance. Instead, efficacy was established by comparing the results with those from previous reports. 2) Given that consecutive cases of LM-PCI were enrolled, this study included cases of acute myocardial infarction or cardiogenic shock, which were excluded in previous studies. This may have led to an increase in clinical events, particularly in terms of mortality. 3) Because this was a retrospective study, there were no standardized criteria for optimal PCI results in intracoronary imaging among the participating institutes, except for the general recommendations of a stent expansion index >80%, minimal stent malapposition, and confirmation of the SB wiring site. 4) The enrollment of LM-PCI or CABG in LM-related diseases varied among the participating institutes, and the expertise and skills of operators performing LM-PCI also differed. These variations may have influenced the study outcomes.